United Therapeutics (NASDAQ:UTHR) Stock Rating Raised to Strong Sell at The Goldman Sachs Group

United Therapeutics (NASDAQ:UTHR) was upgraded by equities research analysts at The Goldman Sachs Group to a “strong sell” rating in a report released on Thursday, Zacks reports.

Other analysts also recently issued research reports about the stock. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Royal Bank Of Canada cut their price target on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Morgan Stanley set a $515.00 price objective on United Therapeutics in a report on Thursday, August 6th. Finally, Bank of America dropped their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $621.00.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $472.21 on Thursday. United Therapeutics has a 1 year low of $409.07 and a 1 year high of $609.35. The stock has a market cap of $20.25 billion, a P/E ratio of 16.89, a P/E/G ratio of 2.49 and a beta of 0.56. The stock has a 50-day simple moving average of $512.06 and a 200-day simple moving average of $540.50.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.41 earnings per share. On average, equities research analysts predict that United Therapeutics will post 26.21 EPS for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 228 shares of the stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $505.87, for a total transaction of $115,338.36. Following the completion of the sale, the director directly owned 5,580 shares of the company’s stock, valued at approximately $2,822,754.60. This trade represents a 3.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $491.57, for a total value of $4,669,915.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at $159,486,445.51. This trade represents a 2.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 355,553 shares of company stock worth $184,183,266. Company insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently modified their holdings of the stock. Arjuna Capital increased its holdings in United Therapeutics by 2.8% in the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after buying an additional 18 shares in the last quarter. Sage Rhino Capital LLC boosted its holdings in shares of United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after acquiring an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC boosted its holdings in shares of United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 24 shares during the last quarter. Meeder Advisory Services Inc. grew its stake in shares of United Therapeutics by 4.1% in the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after acquiring an additional 26 shares during the period. Finally, Kera Capital Partners Inc. raised its holdings in shares of United Therapeutics by 6.1% during the first quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company’s stock valued at $279,000 after purchasing an additional 27 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics is deploying the remainder of its $2 billion share-repurchase authorization through an accelerated share repurchase. A lower share count could support earnings per share and provide some demand for the stock, although investors may continue to debate the capital-allocation decision. United Therapeutics: Strong Catalyst Flow Bodes Well For Near-Term Growth
• Neutral Sentiment: The company’s latest quarterly results exceeded EPS expectations, with $7.27 in adjusted earnings versus an estimated $6.86. However, revenue of $783.3 million missed estimates and declined 1.9% year over year, reinforcing investor focus on whether newer therapies can offset pressure on the established business.
• Negative Sentiment: Goldman Sachs initiated coverage of UTHR with a Sell rating and a $321 price target. The analyst argued that the stock’s premium valuation is inconsistent with a shrinking core business and a challenging launch outlook for Tyvaso and Jenraldi. United Therapeutics downgraded to Sell
• Negative Sentiment: The Goldman report cited reimbursement and payer risks, generic competition, and uncertainty over real-world adoption of Jenraldi. Investors are also watching whether nebulized Tyvaso can secure broader coverage, which could affect future revenue growth. United Therapeutics slips as new Sell rating pressures shares
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $4.7 million, reducing her holdings by 2.84%. The transaction may weigh on sentiment, particularly alongside reported insider selling without recent purchases, though it may also reflect routine personal financial planning. SEC insider transaction filing

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.